US FDA awards six more fast-track vouchers to speed drug reviews
The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo Nordisk, special vouchers that will speed up the review of their medicines, ...
Hemophilia News Today
Biomarin plans to sell rights to hemophilia A therapy Roctavian
Biomarin Pharmaceutical is looking to sell off rights to Roctavian, its approved gene therapy for hemophilia A.
The American Journal of Managed Care
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk MM
A new option is now approved to treat adults living with high-risk smoldering multiple myeloma (MM). 1 The FDA has greenlit ...
Factbox-What Is Metsera, the Target in Pfizer's and Novo Nordisk's Bidding War?
Metsera's lead pipeline asset is MET-097i, a GLP-1 receptor agonist designed for once-monthly injection. Novo's weight-loss drugs Wegovy and Eli Lilly's Zepbound and Mounjaro require weekly injections ...
Study supports wider use of FDA-approved drug for rare muscle disease
UNC School of Medicine researchers have led an international clinical trial of patients with generalized myasthenia gravis, ...
GLP-1 goliath updates demand for top weight loss drug
Novo Nordisk’s closest competitor, Eli Lilly, continues to challenge its dominance in the weight-loss drug market. Eli Lilly, ...
Exclusive: US FDA cleared pricey rare disease drug over reviewer objections
The FDA approved the drug for Barth syndrome despite findings by its data reviewers that the treatment, while safe, was no ...
Labiotech.eu
Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring
Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...
Managed Healthcare Executive
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations
Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...
Yahoo
US FDA approves Bayer's menopause relief drug
The logo of Bayer Mexico is pictured at the company's plant in Lerma, Mexico November 10, 2022. REUTERS/Henry Romero (Reuters) -The U.S. Food and Drug Administration has approved Bayer's drug to ease ...
Bloomberg L.P.
Bayer Wins FDA Approval for Menopause Drug Treating Hot Flashes
Bayer AG won support from US regulators for a menopause drug that’s expected to hit the market in November under the name of Lynkuet. The Food and Drug Administration approved the drug — also known by ...
U.S. News & World Report
US FDA Approves Bayer's Menopause Relief Drug
(Reuters) -Germany's Bayer said on Friday the U.S. health regulator has approved its drug for menopause relief. The drug, branded as Lynkuet, is a non-hormonal treatment designed to relieve ...